Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11990395 | 0.96 | POLB (0.44) | DRD3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11990403 | 0.90 | DRD3 (0.44) | DRD3HTR1ADRD2SIGMAR1 | |
| SCHEMBL20012239 | 0.81 | GHSR (0.50) | DRD3CHRNB4CHRNA3CYP1A2CYP3A4 | |
| SCHEMBL11990452 | 0.81 | GHSR (0.50) | DRD3CHRNB4CHRNA3CYP1A2CYP3A4 | |
| SCHEMBL25568612 | 0.80 | CYP2D6 (0.32) | CHRNB4CHRNA3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11990432 | 0.77 | DRD3 (0.46) | DRD3HTR1ASIGMAR1 | |
| SCHEMBL2991829 | 0.77 | HTR2A (0.49) | DRD3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2426852 | 0.77 | HTR2A (0.49) | DRD3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2429656 | 0.77 | HTR2A (0.49) | DRD3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10464188 | 0.77 | ACHE (0.47) | POLBDRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | Libertas Bio, Inc. | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | TRPA1, TRPV1, TRPV2 | DRD3 977/4885CHRNB4 2047/4885CHRNA3 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.